Why It Matters

Medical device innovation faces a critical bottleneck: FDA approval no longer guarantees timely patient access. Medtronic’s lobbying agenda targets a transformative moment where breakthrough devices proven safe and effective sit in years-long Medicare coverage limbo. Congress is responding with bipartisan urgency—the Ensuring Patient Access to Critical Breakthrough Products Act passed House Ways and Means 38-3—but fraud concerns linger.

Medtronic’s strategy pushes for automatic four-year Medicare coverage for FDA-approved breakthroughs while addressing payment gaps for AI-driven devices and protecting patents amid tariff threats. Success on breakthrough device access appears within reach; patent reform and tariff relief remain murkier.

By the Numbers

Medtronic Inc. spent $2.08 million on in-house lobbying in Q3 2025, deploying four registered lobbyists with deep congressional ties. The lobbying veteran has filed 594 disclosures since 2003, spending over $93 million total.

The in-house team reflects strategic diversity: Andrea Becker Looney served as Chief of Staff to Sen. Bill Frist (R-TN); Jessica Eloise Battaglia worked as Tax and Trade Counsel for Rep. John Lewis (D-GA); Todd E. Gillenwater served as Legislative Director for Rep. David Dreier (R-CA); and Kristina Marie Pisanelli worked for Sen. Patrick Leahy (D-VT).

The Agenda

Medtronic is targeting five major policy areas in this quarter.
The primary focus is accelerating Medicare coverage for FDA-approved breakthrough devices through H.R. 5343 – Ensuring Patient Access to Critical Breakthrough Products Act, which would provide four years of transitional coverage.

The company is establishing Medicare payment pathways for AI and digital health via the Health Tech Investment Act (S. 1399). FDA has approved over 600 AI devices but CMS covers roughly 10.

Patent reform is critical, with lobbying on S. 1553 (PREVAIL Act), S. 1546 (Patent Eligibility Restoration Act), and S. 708 (RESTORE Patent Rights Act) to strengthen protections.

Supply chain resilience targets H.R. 1539 – Medical Device Electronic Labeling Act and S. 998 – Medical Supply Chain Resiliency Act for regulatory modernization and tariff relief.

Broader Context

Breakthrough Device Access faces a critical window. House Ways and Means advanced H.R. 5343 with bipartisan support (38-3), though fraud concerns remain.

AI Payment Gaps represent massive opportunity. FDA approved over 600 AI devices, but CMS established payment for only 10.

Patent Reform gained momentum with Senate Judiciary examining S. 1546 in October 2025, as industry argues current law chills innovation investment.

Supply Chain Disruption poses existential threat. Tariffs on Chinese medical devices hit 55%, with threats of additional 100% tariffs. Medical device industry faces five years to relocate manufacturing, while China announced export controls on rare earth metals critical to MRI scanners.

Between The Lines

Congress is actively legislating on nearly every Medtronic priority, creating momentum and complexity.

H.R. 5343’s overwhelming Ways and Means support (38-3) signals breakthrough device access could succeed, with Rep. Blake Moore (R-UT) arguing "Medicare patients should not wait for FDA-cleared breakthrough devices."

On AI devices, Senate AI Caucus co-chairs introduced S. 1399, acknowledging the FDA-CMS gap where hundreds of approved devices lack payment pathways.

Patent reform bills target strengthening protections, while supply chain legislation addresses labeling modernization and tariff elimination for trusted partners.

Competitive Landscape

Medtronic’s agenda aligns with coordinated sector advocacy. Dexcom Inc. lobbies the same H.R. 1539, while the Medical Device Manufacturers Association engages on FDA processes.

The unified positioning on breakthrough device access, AI payment pathways, and patent reform reflects industry consensus that current systems create investment-chilling gaps between approval and market access.

The Bottom Line

Medtronic’s $2.08 million Q3 2025 lobbying investment targets three interconnected objectives: expedited Medicare coverage for breakthrough devices, AI payment pathways, and patent reform. The company benefits from significant congressional momentum, with breakthrough device legislation gaining overwhelming bipartisan support and AI payment reform advancing in the Senate. However, supply chain vulnerabilities present challenges lobbying alone cannot resolve.

Spot something wrong? Report an issue with this article